Antiviral therapy prolongs survival in immune tolerant hepatitis B patients
A new study demonstrates that the use of antiviral therapy for patients in the immune tolerant phase of hepatitis B (HBV) prolongs overall survival and reduces the risk of the most common form of liver cancer (Hepatocellular Carcinoma, HCC) and scarring of the liver (cirrhosis).
Source: ScienceDaily Headlines - Category: Science Source Type: news
More News: Antiviral Therapy | Cancer | Cancer & Oncology | Carcinoma | Cirrhosis | Hepatitis | Hepatitis B | Hepatocellular Carcinoma | Liver | Liver Cancer | Science | Study | Urology & Nephrology